RECOMMENDATIONS FOR WELL-WOMAN CARE
Preventive care visits provide an excellent opportunity for well-woman care including screening, evaluation of health risks and needs, counseling, and immunizations. Recommendations for Well-Woman Care – A Well-Woman Chart was developed by the Women’s Preventive Services Initiative (WPSI). The Well-Woman Chart outlines preventive services recommended by the WPSI, U.S. Preventive Services Task Force (USPSTF), and Bright Futures based on age, health status, and risk factors. Additional recommendations for immunizations are provided in a separate table from the Advisory Committee on Immunization Practices. Clinical practice considerations, risk assessment methods, and the age and frequency to deliver services are described in the Clinical Summary Tables that accompany the chart.
The Recommendations for Well-Woman Care – A Well-Woman Chart provides a framework for incorporating preventive health services for women into clinical practice. These services may be completed at a single visit or as part of a series of visits that take place over time. Recommendations from the WPSI and the USPSTF for preventive services for pregnant and postpartum women are also provided in the Well-Woman Chart. Comprehensive recommendations for pregnant and postpartum women can be found in ACOG’s practice guidelines and other educational materials. The recommendations are not intended as a statement of the standard of care and do not comprise all proper treatments or methods of care. Providers should use clinical judgment in applying these recommendations to individual patient care, taking into account the needs and resources particular to the locality, the institution, or the type of practice. The Chart is updated annually.
INTERACTIVE WELL-WOMAN CHART
Prevention services for pregnancy and postpartum provided in addition to age-based services listed above.
|Breastfeeding counseling, services & supplies|
|Contraceptive counseling & methods|
|Depression screening Perinatal Depression Screening|
|Folic acid supplementation|
|Gestational diabetes screening|
|Gonorrhea & chlamydia screening|
|Hepatitis B screening|
|HIV testing (each pregnancy)|
|Interpersonal violence screening|
|Preeclampsia prevention with low-dose aspirin|
|Rh(D) blood typing|
|Tobacco screening & counseling|
Recommended by the USPSTF (A or B rating), WPSI, or Bright Futures
Recommended for selected groups
a Additional Bright Futures recommendations include Periodic vision and hearing tests for ages 13-21; risk assessment for anemia for ages 13-21; and fluoride supplementation if needed for ages 13-16. Recommendations on services for adolescents under the age of 13 can be found Here.
b Immunizations should be administered according to the most recent ACIP recommendations
- ACIP = Advisory Committee on Immunization Practices;
- BRCA = breast cancer susceptibility gene;
- CRC = colorectal cancer;
- CVD = cardiovascular disease;
- HIV = human immunodeficiency virus;
- HCV = hepatitis C virus;
- HBV = hepatitis B virus;
- STI = sexually transmitted infection;
- USPSTF = U.S. Preventive Services Task Force;
- WPSI = Women’s Preventive Services Initiative.
*CRITERIA FOR SELECTIVE SCREENING
2. Diabetes screening and management: Overweight or obese for age 40-70 years; previous gestational diabetes but not previously diagnosed with diabetes mellitus when not pregnant for age ≥13 years.
3. Folic acid supplementation: Sexually active and planning or capable of pregnancy.
4. Healthful diet and physical activity counseling: Overweight or obese and have additional CVD risk factors (hypertension, dyslipidemia, abnormal blood glucose levels, diabetes). Specific anticipatory guidance for ages 13-17 may be found in the Bright Futures Guidelines.
5. Lipid Screening:Familial dyslipidemia, risk factors, or high-risk conditions for age 13-16 years; universal screening once between age 17-21 years; clinical judgement for age 22-39 years.
6. Osteoporosis screening: 10-year fracture risk equivalent to an average-risk 65-year old woman based on specific risk factors (parental history of hip fracture, smoking, white race, excess alcohol consumption, low body weight).
7. Statin use to prevent CVD: Age 40 to 75 years; one or more CVD risk factors (i.e., dyslipidemia, diabetes, hypertension, or smoking); and calculated 10-year risk of a CVD event ≥10%.
8. Urinary incontinence screening: Screen all women age 18 and older and younger women if postpartum.
9. Gonorrhea and chlamydia screening: New sex partner, more than one sex partner, a sex partner with concurrent partners, or a sex partner who has an STI; inconsistent condom use among persons who are not in mutually monogamous relationships; previous or coexisting STI; and exchanging sex for money or drugs. Prevalence is also higher among incarcerated populations, military recruits, and patients receiving care at public STI clinics.
10. Hepatitis B screening: Born in a country with a prevalence of HBV infection ≥2%; lack of vaccination in infancy in U.S.-born persons with parents from a country or region with prevalence ≥8%; HIV-positive persons; injection drug users; and household contacts or sexual partners of persons with HBV infection.
11. Hepatitis C screening: One-time screening for asymptomatic adults age 18-79 without known liver disease. Repeat screening and screen at other ages if increased risk: past or current injection drug use; receipt of a blood transfusion before 1992; long-term hemodialysis; born to an HCVinfected mother; incarceration; intranasal drug use; getting an unregulated tattoo; and other percutaneous exposures (e.g. health care workers).
12.HIV preexposure prophylaxis (PrEP): Candidates for include 1) heterosexually active women with: a serodiscordant sex partner (i.e., in a sexual relationship with a partner living with HIV); or inconsistent use of condoms during sex with a partner whose HIV status is unknown and who is at high risk; or an STI with syphilis or gonorrhea within the past 6 months; 2) uses injection drugs and shared use of drug injection equipment; or has risk of sexual acquisition of HIV based on above; 3) engaged in transactional sex, such as for money, drugs, or other.
13. Sexually transmitted infection prevention counseling: New sex partner, more than one sex partner, a sex partner with concurrent partners, or a sex partner who has an STI; inconsistent condom use among persons who are not in mutually monogamous relationships; previous or coexisting STI; and exchanging sex for money or drugs. Prevalence is also higher among incarcerated populations, military recruits, and patients receiving care at public STI clinics.
14. Syphilis screening: Women with HIV; high prevalence communities or populations; history of incarceration; exchanging sex for money or drugs.
15. Latent tuberculosis infection: Persons from countries with increased tuberculosis prevalence; living in high-risk congregate settings (e.g., homeless shelters, correctional facilities); exposure to individuals with active tuberculosis, such as health care workers and workers in high-risk congregate settings; immunosuppressed individuals.
16. Breast cancer screening: No specific criteria, decisions about screening are made on an individual basis through a shared-decision making process.
17. Lung cancer screening: 30 pack-year smoking history and currently smoke or have quit within the past 15 years
18. Medications to reduce breast cancer risk: Major risk factors for breast cancer include increasing age, family history of breast or ovarian cancer (especially among first-degree relatives and onset before age 50 years), history of atypical hyperplasia or other nonmalignant high-risk breast lesions, previous breast biopsy, and extremely dense breast tissue. Models suggest that women with an estimated 5-year breast cancer risk of 3% or greater are likely to have more benefit than harm, although the balance of benefits and harms depends on age, race or ethnicity, the medication used, and whether the patient has a uterus.
19. Skin cancer counseling: Fair skin, light hair and eye color, freckles, sunburn easily.
20. Perinatal depression interventions: Counseling interventions for women with one or more of the following: a history of depression, current depressive symptoms that may not reach a diagnostic threshold, socioeconomic risk factors such as low income or adolescent or single parenthood, recent intimate partner violence, or mental health–related factors such as elevated anxiety symptoms or a history of significant negative life events.
21. Preeclampsia prevention with low-dose aspirin: History of preeclampsia, especially when accompanied by an adverse outcome; multifetal gestation; chronic hypertension; type 1 or 2 diabetes mellitus; renal disease; autoimmune disease (systemic lupus erythematous, antiphospholipid syndrome).
22. Diabetes screening after pregnancy: Previous gestational diabetes but not previously diagnosed with diabetes mellitus when not pregnant.
Women’s Preventive Services Initiative. Recommendations for well-woman care – a well-woman chart. Washington, DC: ACOG Foundation; 2018. Available at: https://www.womenspreventivehealth.org/wp-content/uploads/WellWomanChart.pdf. Retrieved August 26, 2019.
Women’s Preventive Services Initiative. Recommendations for well-woman care: clinical summary tables. Washington, DC: ACOG Foundation; 2018. Available at: https://www.womenspreventivehealth.org/wp-content/uploads/ClinicalSummaryTables.pdf. Retrieved August 26, 2019.
All inquiries regarding HRSA acceptance and support of the WPSI recommendations should be sent to email@example.com. Inquiries regarding the content or evidence related to the recommendations can be sent to firstname.lastname@example.org.
©2018, Content owned by the ACOG Foundation, all Marks and Rights Reserved. This project was supported by the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) under grant number UHOMC29940, Bright Futures for Women’s Health: Standard Practice Guidelines for Well Women Care. This information or content and conclusions are those of the author and should not be construed as the official position nor policy of, nor should any endorsements be inferred by HRSA, HHS, or the U.S. Government.